5-Amino-1MQ (10mg)
5-Amino-1MQ dosing protocols center on this selective, cell-permeable NNMT (Nicotinamide N-methyltransferase) inhibitor studied for its potential to support fat metabolism, preserve lean muscle mass, and increase intracellular NAD+ levels. By inhibiting NNMT, 5-Amino-1MQ may help restore cellular energy balance and activate SIRT1 pathways associated with metabolic efficiency. This educational protocol outlines a subcutaneous injection approach.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
Research monograph
See the full 5-Amino-1MQ encyclopedia page with mechanism, evidence tier, related variants and research context.
How It Works
5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small molecule that selectively inhibits Nicotinamide N-methyltransferase (NNMT). NNMT is an enzyme that methylates nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as a methyl donor. In states of obesity and metabolic dysfunction, NNMT is often overexpressed in adipose tissue, depleting nicotinamide and reducing NAD+ availability. By inhibiting NNMT, 5-Amino-1MQ may spare nicotinamide for NAD+ synthesis, activating SIRT1 pathways associated with mitochondrial biogenesis and fat oxidation.
Quick Start
- Reconstitution: Add 2.0 mL bacteriostatic water → 5 mg/mL concentration.
- Typical Daily Range: 2.5–5 mg once or twice daily (subcutaneously).
- Storage: Lyophilized: freeze at −20 °C; after reconstitution, refrigerate at 2–8 °C; use within 2–4 weeks.
Subcutaneous Protocol (2 mL = 5 mg/mL)
Route: Subcutaneous | Frequency: Once or twice daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Days 1–2 (Tolerance) | 2.5 mg once | 50 Units (0.50 mL) |
| Days 3+ (Standard) | 5 mg once | 100 Units (1.00 mL) |
| Alternative BID | 2.5 mg twice | 50 Units (0.50 mL) |
Studies report administration once or twice daily subcutaneously. Due to a plasma half-life of ~3.8–6.9 hours, twice-daily (BID) dosing may provide more stable NNMT inhibition. Note: A 10 mg vial provides only 2–4 days of research material at these doses.
Related compounds
Reconstitution Steps
- Remove vial from freezer (−20 °C) and allow to equilibrate to room temperature for 15–20 minutes.
- Draw 2.0 mL of bacteriostatic water with a sterile syringe.
- Inject slowly down the side of the vial; avoid foaming.
- Gently swirl/rotate until dissolved (do not shake vigorously).
- Label and refrigerate at 2–8 °C, protecting from light; use within 2–4 weeks.
Protocol Overview
- Goal: Support metabolic efficiency via NNMT inhibition, potentially enhancing fat oxidation and NAD+ levels.
- Schedule: Daily subcutaneous injections; each vial provides 2–4 days of research material.
- Storage: Lyophilized frozen at −20 °C; reconstituted refrigerated at 2–8 °C.
Dosing Protocol
- Initiation: 2.5 mg once daily to assess tolerance.
- Target: 5 mg once daily or 2.5 mg twice daily (BID).
- Frequency: Once or twice daily (subcutaneously).
- Vial Duration: A 10 mg vial lasts for 2–4 days at research doses.
- Timing: Morning administration is preferred; BID dosing can be split morning/afternoon.
- Break between cycles: After the cycle, a 2–4 week washout is recommended. NNMT inhibition regulates NAD+ levels—the washout prevents metabolic adaptation.
Washout & Cycle Restart
When can I restart?
After the cycle, a 2–4 week washout is recommended. NNMT inhibition regulates NAD+ levels—the washout prevents metabolic adaptation.
Minimum wait period: 2 weeks
Storage Instructions
- Lyophilized: Store at −20 °C in dry, dark conditions; stable for up to 24 months.
- Reconstituted: Refrigerate at 2–8 °C; use within 2–4 weeks.
- Allow vials to reach room temperature before reconstitution.
- Do not re-freeze reconstituted solution.
Important Notes
- The 10 mg vial is suitable for short-term tolerance assessment; extended protocols require multiple vials.
Potential Benefits & Side Effects
Potential Benefits:
- May support reductions in fat mass while preserving lean muscle tissue in animal models.
- Associated with increased NAD+ levels and SIRT1 activation in preclinical studies.
- Enhanced grip strength was observed in aged mice in combination with exercise.
- Generally well-tolerated; occasional reports of mild headache, transient nervousness, or injection site reactions.
- Long-term human safety data has not been established; the compound remains investigational.
Potential Side Effects:
- Nausea or stomach discomfort (mild, initial).
- Headache (transient).
- Fatigue during metabolic adaptation.
- Dry mouth or increased thirst.
- Potential hypoglycemia due to NNMT inhibition.
- Limited long-term human safety data.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Hepatotoxicity (preclinical)
As an NNMT inhibitor, 5-amino-1MQ has shown hepatotoxicity at high doses in rodents. No human safety studies exist.
📄 Biochem Pharmacol 2020References
- Nature Medicine (2014) — NNMT inhibition protects against diet-induced obesity
View Source - PMC (2024) — NNMT inhibition mitigates obesity-associated metabolic dysfunctions
View Source - Frontiers in Pharmacology (2024) — NNMT: a new therapeutic target for metabolic syndrome
View Source - PubMed (2021) — Pharmacokinetic study of 5-amino-1-methylquinolinium
View Source - Journal of Medicinal Chemistry (ACS) — NNMT inhibitors with enhanced potency
View Source
External Sources & Regulatory Status
Regulatory Approvals
Research-only — NNMT inhibitor
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →